We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$558M
AUM Growth
+$124M
Cap. Flow
+$99.9M
Cap. Flow %
17.91%
Top 10 Hldgs %
37.3%
Holding
93
New
18
Increased
51
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.2M
2
MDT icon
Medtronic
MDT
+$25.2M
3
CI icon
Cigna
CI
+$8.15M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$7.58M
5
AET
Aetna Inc
AET
+$7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$24.6M
2
UNH icon
UnitedHealth
UNH
+$14.8M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$11.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$9.64M
5
ABBV icon
AbbVie
ABBV
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 75.87%
2 Industrials 2.28%
3 Financials 1.34%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYBX
51
DELISTED
CYBERONICS INC
CYBX
$4.03M 0.72%
+64,500
New +$3.93M
AVNR
52
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$3.95M 0.71%
700,000
+400,000
+133% +$1.84M
MDCO
53
DELISTED
Medicines Co
MDCO
$3.93M 0.7%
135,100
+15,100
+13% +$403K
WCG
54
DELISTED
Wellcare Health Plans, Inc.
WCG
$3.85M 0.69%
51,500
– –
CRL icon
55
Charles River Laboratories
CRL
$12.8B
$3.81M 0.68%
71,250
+21,750
+44% +$1.19M
ABCO
56
DELISTED
Advisory Board Co
ABCO
$3.76M 0.67%
72,500
+41,425
+133% +$2.24M
CVD
57
DELISTED
COVANCE INC.
CVD
$3.68M 0.66%
43,000
+10,500
+32% +$936K
ICPT
58
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.57M 0.64%
15,100
+2,100
+16% +$553K
ARAV
59
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.48M 0.62%
+20,709
New +$3.57M
PRTA icon
60
Prothena Corp
PRTA
$450M
$3.38M 0.61%
150,000
+85,000
+131% +$2.13M
TNDM icon
61
Tandem Diabetes Care
TNDM
$1.56B
$3.17M 0.57%
+19,500
New +$3.32M
WX
62
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$3.17M 0.57%
96,500
+44,000
+84% +$1.51M
RLYP
63
DELISTED
RELYPSA INC COM
RLYP
$3.06M 0.55%
+126,000
New +$2.99M
CFN
64
DELISTED
CAREFUSION CORPORATION
CFN
$3.02M 0.54%
+68,000
New +$2.81M
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.55B
$2.94M 0.53%
65,500
+14,000
+27% +$576K
AGN
66
DELISTED
Allergan Inc
AGN
$2.75M 0.49%
+16,250
New +$2.53M
CBST
67
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$2.72M 0.49%
39,000
+9,000
+30% +$612K
NVAX icon
68
Novavax
NVAX
$1.31B
$2.63M 0.47%
28,500
+12,250
+75% +$1.08M
REGN icon
69
Regeneron Pharmaceuticals
REGN
$80.8B
$2.12M 0.38%
7,500
– –
ALKS icon
70
Alkermes
ALKS
$8.25B
$2.08M 0.37%
41,250
+5,750
+16% +$265K
FPRX
71
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.94M 0.35%
125,000
-50,000
-29% -$717K
INFI
72
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.94M 0.35%
152,500
+55,000
+56% +$573K
ARWR icon
73
Arrowhead Research
ARWR
$12.4B
$1.65M 0.3%
115,000
+40,000
+53% +$524K
TBPH icon
74
Theravance Biopharma
TBPH
$877M
$1.59M 0.29%
+50,000
New +$1.51M
NVDQ
75
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.48M 0.27%
+90,000
New +$1.48M
1 2
3
4

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rock Springs Capital Management held 93 positions worth $558M, up 29% from $434M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management deployed $99.9M of net new capital in Q2 2014, opening 18 new positions and adding to 51 existing holdings. Its largest new stake was Merck: 497,800 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 79% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $4.46M trimmed.

  • Rock Springs Capital Management's largest Q2 2014 buy was Merck: 497,800 shares worth $27.5M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q2 2014, an estimated $5.88M increase.
  • Rock Springs Capital Management's biggest Q2 2014 reduction was AbbVie, cutting an estimated $4.46M.
  • Rock Springs Capital Management fully exited Johnson & Johnson in Q2 2014, selling an estimated $24.6M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $558M portfolio in Q2 2014.
  • Rock Springs Capital Management opened 18 new positions and closed 15 in Q2 2014.
  • Rock Springs Capital Management's portfolio value rose 29% quarter-over-quarter to $558M.

Based on Rock Springs Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.